Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | DNM1 | Q05193 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | LAP3 | P28838 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19433888 | 0.82 | OPRM1 (0.40) | OPRM1SPHK1TP53DNM1MEN1 | |
| SCHEMBL29647839 | 0.79 | OPRM1 (0.48) | OPRM1SPHK1DNM1TSHR | |
| SCHEMBL16782308 | 0.79 | OPRM1 (0.48) | OPRM1SPHK1DNM1TSHR | |
| SCHEMBL21878556 | 0.78 | OPRM1 (0.39) | OPRM1SPHK1TP53CA1 | |
| SCHEMBL23806431 | 0.78 | OPRM1 (0.39) | OPRM1SPHK1DNM1MEN1KMT2A | |
| SCHEMBL27969022 | 0.76 | OPRM1 (0.46) | OPRM1SPHK1TP53DNM1LAP3 | |
| SCHEMBL30117301 | 0.75 | OPRM1 (0.44) | OPRM1SPHK1TP53DNM1CA1 | |
| SCHEMBL24604226 | 0.74 | DNM1 (0.39) | SPHK1DNM1MEN1KMT2AALDH1A1 | |
| SCHEMBL29678590 | 0.73 | DNM1 (0.41) | OPRM1DNM1ALDH1A1TSHRCA1 | |
| SCHEMBL2118765 | 0.73 | OPRM1 (0.42) | OPRM1SPHK1TP53DNM1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203083-A1 | NUCLEOTIDE ANALOGUES | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-06-29 | — | — | US | disclosed |
| US-20230028359-A1 | NUCLEOTIDE ANALOGUES | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230028359-A1 | NUCLEOTIDE ANALOGUES | ITPA, POLB, NUDT1 | OPRM1 3231/4885SPHK1 3016/4885TP53 635/4885 |
| US-20230203083-A1 | NUCLEOTIDE ANALOGUES | ITPA, POLB, NUDT1 | OPRM1 3231/4885SPHK1 3016/4885TP53 635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.